CNBC   |  April 25, 2014

Allergan, Valeant perfect match: CEO

CNBC's David Faber and Jeffrey Ubben, ValueAct Capital Partners CEO, discuss Valeant Pharmaceuticals bid for Allergan and why Valeant needed investor Bill Ackman involved in the deal.

Share This:

Sorry, we do not have a transcript available for this video at this time.